The US Food and Drug Administration (FDA) has accepted Sobi North America's avatrombopag (DOPTELET) supplemental new drug application (sNDA) to treat paediatric immune thrombocytopenia. The therapy is ...
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration ...
With several launches underway and partnerships driving sales growth, Sobi is gaining momentum in its quest to become a force in hematology. During the second quarter, the Swedish drugmaker saw the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results